Abstract: Lung cancer has a high incidence and mortality in developed countries. About 75%～80% of lung cancersare nonsmall cell lung cancers (NSCLC). Due to deficiency of techniques for early diagnosis, 60%～70% of NSCLC pa-tients are found at advanced stages when diagnosed, leading to little chance for radical operation. Such cases can only betreated with chemotherapy or radiotherapy. There has been no breakthrough in the treatment and prognosis of those cases.The platinumbased combination regimens remain the first priorities for NSCLC cases. But because of individual differ-ences, the response rate is only 25%～30% and the 2year survival is about 15%. The sensitivities to regimens vary greatlyeven in NSCLC cases with same pathology and staging. The concept of individual therapy has been brought forward in re-cent years. Researches on molecular mechanisms of combination regimens have discovered correlations between somecancer molecular indices and the sensitivities by now. Individual regimens targeting different molecular indices may besignificant in improving the survival of patients with late stage NSCLC. Identification of variations in some specific genesas the drug resistance indications will enable the most sensitive therapy for individuals. More multicentered clinical trialsand standardized methods and evaluation of results will be needed for clinical application.